Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Article

Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers

Masaaki Komatsu, Keiko Hiyama, Keiji Tanimoto, Mayu Yunokawa, Keiko Otani, Megu Ohtaki, Eiso Hiyama, Junzo Kigawa, Michitaka Ohwada, Mitsuaki Suzuki, Nobutaka Nagai, Yoshiki Kudo and Masahiko Nishiyama
Masaaki Komatsu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keiko Hiyama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keiji Tanimoto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mayu Yunokawa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keiko Otani
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Megu Ohtaki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eiso Hiyama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Junzo Kigawa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michitaka Ohwada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mitsuaki Suzuki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nobutaka Nagai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshiki Kudo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masahiko Nishiyama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-05-0408 Published March 2006
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

We attempted to identify potent marker genes using a new statistical analysis and developed a prediction system for individual response to platinum/paclitaxel combination chemotherapy in ovarian cancer patients based on the hypothesis that expression analysis of a set of the key drug sensitivity genes for platinum and paclitaxel could allow us to predict therapeutic response to the combination. From 10 human ovarian cancer cell lines, genes correlative in the expression levels with cytotoxicities of cisplatin (CDDP) and paclitaxel were chosen. We first selected five reliable prediction markers for the two drugs from 22 genes already known as sensitivity determinants and then identified another 8 novel genes through a two-dimensional mixed normal model using oligomicroarray expression data. Using expression data of genes quantified by real-time reverse transcription-PCR, we fixed the best linear model, which converted the quantified expression data into an IC50 of each drug. Multiple regression analysis of the selected genes yielded three prediction formulae for in vitro activity of CDDP and paclitaxel. In the same way, using the same genes selected in vitro, we then attempted to develop prediction formulae for progression-free survival to the platinum/paclitaxel combination. We therefore constructed possible formulae using different sets of 13 selected marker genes (5 known and 8 novel genes): Utility confirmation analyses using another nine test samples seemed to show that the formulae using a set of 8 novel marker genes alone could accurately predict progression-free survival (r = 0.683; P = 0.042). [Mol Cancer Ther 2006;5(3):767–75]

Keywords:
  • personalized medicine
  • drug sensitivity
  • oligonucleotide array
  • two-dimensional mixed normal model
  • ovarian cancer

Footnotes

  • ↵7 http://www.ncbi.nlm.nih.gov.geo/.

  • ↵8 http://apollo.rbm.hiroshima-u.ac.jp/.

  • ↵9 Supplementary material for this article is available at Molecular Cancer Therapeutics online (http://aacrjournals.org/).

  • Grant support: Science Promotion Fund of the Ministry of Education, Culture, Sports, Science and Technology of Japan, Grant-in-Aid for Scientific Research (B) (2) 14370390 (M. Nishiyama), and Grant-in-Aid for University and Industry Collaboration (A) (M. Nishiyama).

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted January 18, 2006.
    • Received October 6, 2005.
    • Revision received January 6, 2006.
  • American Association for Cancer Research
View Full Text
PreviousNext
Back to top
Molecular Cancer Therapeutics: 5 (3)
March 2006
Volume 5, Issue 3
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers
Masaaki Komatsu, Keiko Hiyama, Keiji Tanimoto, Mayu Yunokawa, Keiko Otani, Megu Ohtaki, Eiso Hiyama, Junzo Kigawa, Michitaka Ohwada, Mitsuaki Suzuki, Nobutaka Nagai, Yoshiki Kudo and Masahiko Nishiyama
Mol Cancer Ther March 1 2006 (5) (3) 767-775; DOI: 10.1158/1535-7163.MCT-05-0408

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers
Masaaki Komatsu, Keiko Hiyama, Keiji Tanimoto, Mayu Yunokawa, Keiko Otani, Megu Ohtaki, Eiso Hiyama, Junzo Kigawa, Michitaka Ohwada, Mitsuaki Suzuki, Nobutaka Nagai, Yoshiki Kudo and Masahiko Nishiyama
Mol Cancer Ther March 1 2006 (5) (3) 767-775; DOI: 10.1158/1535-7163.MCT-05-0408
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: Disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non–small cell lung cancer cells (H1299)
  • Identification of a small topoisomerase I–binding peptide that has synergistic antitumor activity with 9-aminocamptothecin
Show more Article
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement